


PHARMACEUTICAL 2019

immun•gen

ImmunoGen Inc. Rank 225 of 371



RealRate

PHARMACEUTICAL 2019

ImmunoGen Inc. Rank 225 of 371



The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 63% points. The greatest weakness of ImmunoGen Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is -232%, being 99% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	278,781
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	70,660
Liabilities, Non-Current	84,665
Other Assets	3,709
Other Compr. Net Income	0
Other Expenses	14,419
Other Liabilities	129,084
Other Net Income	3,332
Property and Equipment	12,891
Research and Development	174,456
Revenues	53,446
Selling, General and Administrative Expense	36,746

Output Variable	Value in 1000 USD
Assets	295,381
Liabilities	284,409
Expenses	225,621
Stockholders Equity	10,972
Net Income	-168,843
Comprehensive Net Income	-168,843
Economic Capital Ratio	-232%